The effectiveness of intermittent rat parathyroid hormone (1-34) treatment on low bone mass due to oestrogen or androgen depletion in skeletally mature rats

Aging Male

Volumn 13, Issue 1, 2010, Pages 59-73

  Montero, M ^a   Serfati, D ^b   Luna, S ^c   Diaz Curiel M ^a   Carrascal, M T ^d   Gomez, S ^c   De La Piedra, C ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c UNIVERSITY OF CÁDIZ   (Spain)

^d UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

Low bone mass; Orchidectomy; Ovariectomy; Parathyroid hormone; Rat

Indexed keywords

ANDROGEN; ESTROGEN; PARATHYROID HORMONE[1-34];

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; CASTRATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; MALE; MORPHOMETRICS; NONHUMAN; ORCHIECTOMY; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT;

ANDROGENS; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; CALCIUM; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; MALE; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE; RATS; RATS, WISTAR;

EID: 77249144938     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685530903536650     Document Type: Article

References (48)

1. Eastell R. Pathogenesis of postmenopausal osteoporosis. In: Favus MJ, editor. Metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington: ASBMR; 2003. pp 314-316.
2. Boonen S, Kaufman JM, Goemaere S, Bouillon R, Vanderschueren D. The diagnosis and treatment of male osteoporosis: Defining, assessing, and preventing skeletal fragility in men. Eur J Intern Med 2007;18:6-17.
3. Riggs BL and Melton LJ 3rd. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002;17:11-14.
4. NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. JAMA 2001;285:785-795.
5. González Macías J. Osteoporosis: definición y etiología. In: Manual práctico de osteoporosis y enfermedades del metabolismo mineral, Santander, Spain: Jarpyo; 2004. pp 99-103.
6. Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002;13:97-104.
7. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi J, Waldegger L, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-551.
8. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-528.
9. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G; Osteoporosis Research Advisory Group (ORAG). A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001;12:140-151.
10. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-523.
11. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-516.
12. Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int 2007;18:45-57.
13. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY. Strontium ranelate: dosedependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-2066.
14. Kleerekoper M. Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporos Int 2006;17:1707-1715.
15. Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982;110:506-512.
16. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R. Effects of daily treatment with parathyroid hormone on bone microachitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1864-11853
17. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40:1434-1446.
18. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
19. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056.
20. Ruffoni D, Fraztl P, Roschger P, Klaushofer K, Weinkamer R. The bone mineralization as a fingerprint of the mineralization process. Bone 2007;40, 1308-1319.
21. Diaz-Curiel MD, Calero JA, Guerrero R, Gala J, Gazapo R, de la Piedra C. Effects of LY-117018 HCl on bone remodeling and mineral density in the oophorectomized rat. The Am J Obstet Gynecol 1998;178:320-325.
22. Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res 2000;15:1085-1098.
23. Gala Paniagua J, Díaz-Curiel M, de la Piedra Gordo C, Castilla Reparaz C, Torralbo García M. Bone mass assessment in rats by dual energy X-ray absorptiometry. Brit J Radiol 1998;71:754-758.
24. Thomsen JS, Ebbesen EN, Mosekilde L. A new method of comprehensive static histomorphometry applied on human lumbar vertebral cancellous bone. Bone 2000;27:129-138.
25. Kneissel M, Boyde A, Gasser JA. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH (1-34). Bone 2001;28:237-250.
26. Gomez S, and Boyde A. Correlated alkaline phosphatase histochemistry and quantitative backscattered electron imaging in the study of rat incisor ameloblasts and enamel mineralization. Microsc Res Tech 1994;29:29-36.
27. Sogaard CH, Mosekilde L, Thomsen JS, Richards A, McOsker JE. A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model. Bone 1997;20:439-449.
28. Turner RT, Evans GL, Cavolina JM, Halloran B, Morey- Holton E. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 1998;139:4086-4091.
29. Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 2000;15:1517-1525.
30. Gabet Y, Kohavi D, Müler R, Chorev M, Bab I. Intermittently administered parathyroid hormone 1-34 reverses bone loss and structural impairment in orchiectomized adult rats. Osteoporos Int 2005;16:1436-1443.
31. Qi H, Li M, Wronski TJ. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 1995;10:948-955.
32. Banu J, Kalu DN. Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague- Dawley rats. Bone 2002;31:173-179.
33. Zhang KQ, Chen JW, Li GF, Tian XY, Huang LF, Bao LH, Wang ML. Effect of intermittent injection of recombinant human parathyroid hormone on bone histomorphometry of ovariectomized rats. Acta Pharmacol Sin 2002;23:659-662.
34. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-2134.
35. Black DM, Greenspan SL, Ensrud KE, Palermo L,McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-1215.
36. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349: 1216-1226.
37. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-543. (Pubitemid 36241071)
38. Turner RT, Evans GL, Lotinum S, Lapke PD, Iwaniec UT, Morey-Holton E. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 2007;22:64-71.
39. Crandall C. Parathyroid hormone for treatment of osteoporosis. Arch Intern Med 2002;162:2297-2309.
40. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect or parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
41. Dempster DW and Lindsay R Pathogenesis of osteoporosis. Lancet 1993;341:797-801.
42. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev 1994;15:275-300.
43. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The actions and interactions of sex steroids and growth factors/ cytokines on the skeleton. Mol Endocrinol 1999;13:819-828
44. Sato M, Zeng GQ, Turner CH. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 1997;138:4330-4337.
45. Tsuchida T, Miyakoshi N, Kudo T, Tamura Y, Kasukawa Y, Suzuki K, Sato K. Restoring effect of human parathyroid hormone (1-34) on trabecular connectivity in ovariectomized rats. Tohoku J Exp Med 2001;194:213-221.
46. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632-3638.
47. Friedl G, Turner RT, Evans GL, Dobnig H. Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. J Orthop Res 2007;25:1454-1464.
48. Oxlund H, Dalstra M, Ejersted C, Andreassen TT. Parathyroid hormone induces formation of new cancellous bone with substantial mechanical strength at a site where it had disappeared in old rats. Eur J Endocrinol 2002;146:431-438.